Topics:

Lung Cancer

Lung Cancer

Patients who underwent low-dose CT for lung cancer screening and received false-positives benefited from counseling.

Epidermal growth factor receptor tyrosine kinase inhibitors may not be the best option for some patients with nonsmall cell lung cancer, but an ALK inhibitor, crizotinib, proves a winner.

GlaxoSmithKline has stopped a phase III trial of a novel lung cancer immunotherapeutic agent, after determining that it may not be possible to identify which genetic subgroups may benefit from the treatment.

A biomarker and five clinical factors help to predict which patients with nonsmall-cell lung cancer are at high risk for lung inflammation after radiotherapy.

The new ALK inhibitor certinib showed strong antitumor activity in a phase I expansion study of patients with advanced non-small-cell lung cancer (NSCLC).

In a phase I trial, non–small-cell lung cancer (NSCLC) patients with tumors that expressed PD-L1 had significantly better outcomes with MK-3475 therapy compared with patients with PD-L1–negative tumors.

In this interview we discuss the oncogenes driving the development of squamous cell carcinoma of the lung, a type of non-small-cell lung cancer.

Pages

Subscribe to Lung Cancer on [sitename]

CME Center

Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.

By clicking Accept, you agree to become a member of the UBM Medica Community.